血清神经丝蛋白与早期多发性硬化脑萎缩及残疾进展相关
本研究基于随机双盲试验,比较利鲁唑与安慰剂对血清神经丝蛋白的影响,并分析纵向临床与MRI结局和血清Nf水平的关系。结果显示利鲁唑无显著治疗效应,NfL随时间下降,其变化与EDSS变化和神经心理学结局相关,高基线NfL者脑体积下降更快,较高且升高的NfL预测更多钆增强病灶。
要点
- 血清NfL可作为早期多发性硬化神经轴索损伤的标志物。
- 高基线NfL与全脑萎缩加速及急性白质病灶形成相关。
- 利鲁唑未观察到对血清Nf水平或临床结局的治疗效应。
核心结论
- 血清NfL可能作为早期多发性硬化神经轴索损伤和疾病活动性的非侵入性生物标志物。
研究设计与样本
- 随机双盲试验中,利鲁唑与安慰剂作为每周干扰素β-1a IM的附加治疗,随机化后3个月开始。
- 纵向血清样本来自22名利鲁唑组和20名安慰剂组参与者,随访24个月。
- Nf测量采用ELISA和电化学发光免疫分析。
主要发现
- 未观察到利鲁唑的治疗效应。
- NfL水平随时间下降(24个月时p=0.007),NfH未变化(p=0.997)。
- NfL变化与EDSS变化(p=0.009)和神经心理学结局相关。
- 高基线NfL患者脑体积下降更快(12个月p=0.05,24个月p=0.008),关系在24个月增强(交互作用p=0.024)。
- 较高且升高的NfL预测更多钆增强病灶(两者p<0.001)。
临床怎么用
- 血清NfL可用于监测早期多发性硬化的神经轴索损伤和疾病活动性。
- 高基线NfL提示脑萎缩风险较高,可辅助临床评估。
局限性
- 样本量较小(利鲁唑组22例,安慰剂组20例)。
- NfL下降可能反映回归均值或干扰素β-1a的治疗效应,需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate a potential effect of riluzole on serum neurofilaments (Nf) compared to placebo and the relationship between longitudinal clinical and MRI outcomes and serum Nf levels. METHODS: Serum samples were obtained from participants enrolled in a randomized double-blind trial of neuroprotection with riluzole vs placebo as an add-on to weekly interferon-β (IFN-β)-1a IM initiated 3 months after randomization. Nf measurements were performed by ELISA and electrochemiluminescence immunoassay. RESULTS: Longitudinal serum samples were available from 22 riluzole and 20 placebo participants over 24 months. There was no observed treatment effect with riluzole. Nf light chain (NfL) levels decreased over time (p = 0.007 at 24 months), whereas the Nf heavy chain was unchanged (p = 0.997). Changes in NfL were correlated with EDSS change (p = 0.009) and neuropsychological outcomes. Brain volume decreased more rapidly in patients with high baseline NfL (p = 0.05 at 12 months and p = 0.008 at 24 months) and this relationship became stronger at 24 months (p = 0.024 for interaction). Higher and increasing NfL predicted higher number of gadolinium-enhancing lesions (p < 0.001 for both). CONCLUSIONS: Our findings support the potential value of serum NfL as a marker of neuroaxonal injury in early multiple sclerosis. Its reduction over time could represent regression to the mean, or a possible treatment effect of IFN-β-1a. The association with whole brain atrophy and the formation of acute white matter lesions has relevant implications to use serum NfL as a noninvasive biomarker of the overall consequences of brain damage and ongoing disease activity. CLINICALTRIALSGOV IDENTIFIER: NCT00501943.
引用
- Kuhle J, Nourbakhsh B, Grant D, et al. Serum neurofilament is associated with progression of brain atrophy and disability in early MS. Neurology. 2017. PMID: 28148632. doi:10.1212/WNL.0000000000003653
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。